查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020076

肺癌篩檢市場規模、佔有率、成長及全球產業分析：按類型、應用和地區的洞察，2026-2034年的預測

Lung Cancer Screening Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 139 Pages | 商品交期: 請詢問到貨日

價格

肺癌篩檢市場的成長要素

全球肺癌篩檢市場在2025年達到38.4億美元，預計2026年成長至41.6億美元，到2034年達到86.7億美元，2026年至2034年的年複合成長率為9.61%。北美市場領先，在2025年佔據55.13%的市場佔有率，這得益於其強大的篩檢項目和先進的醫療基礎設施。

肺癌主要與吸菸有關，仍然是全球最常見、最致命的癌症之一。早期篩檢在降低死亡率方面發揮非常重要的作用，這大幅促進了全球先進診斷技術的應用。

市場趨勢

篩檢技術的進步

市場正經歷快速的技術進步，尤其是在低劑量CT（LDCT）、液態生物檢體和人工智慧診斷工具等篩檢方法方面。這些創新在提高早期檢出率的同時，也減少了侵入性手術的需求。

奈米顆粒感測器和人工智慧輔助成像等新型技術顯著提高篩檢的準確性和效率。此外，液態生物檢體的發展使得非侵入性癌症檢測成為可能，讓篩檢更加便捷，減輕了患者的負擔。

市場成長要素

肺癌發生率上升

全球肺癌發生率的上升（主要歸因於吸煙和生活方式的改變）是推動市場成長的主要因素。人們對早期診斷意識的提高以及醫療機構篩檢力度的加大，進一步促進了市場擴張。

政府計畫和宣傳宣傳活動鼓勵高風險族群定期接受篩檢，導致每年進行的診斷測試數量增加。

先進診斷工具的廣泛應用

除了先進的成像技術日益普及，已開發國家優惠的保險償付政策也推動了篩檢方案的採用。此外，生物技術公司與醫療保健公司之間的合作加速診斷技術的創新。

抑制因子

篩檢測試高成本

儘管技術不斷進步，但篩檢測試（尤其是電腦斷層掃描）的高成本仍然是中低收入國家推廣應用的一大障礙。有限的保險覆蓋範圍和不足的醫療基礎設施進一步限制了這些測試的普及。

此外，發展中地區熟練的放射科醫生和診斷專家的短缺也對市場成長構成挑戰。

市場區隔分析

依類型分類的癌症

從市場區隔來看，肺癌分為非小細胞肺癌（NSCLC）和小細胞肺癌（SCLC）。

  • 非小細胞肺癌（NSCLC）細分市場佔據主導地位，由於其在全球範圍內的高發病率，預計到2026年將佔市場佔有率的87.8%。
  • 此外，由於人們對小細胞肺癌（SCLC）的認知提高和篩檢力度加大，SCLC 市場也為市場做出了重大貢獻。

依診斷方法

市場分為低劑量螺旋電腦斷層掃描和胸部X光檢查。

  • 由於低劑量電腦斷層掃描將佔據市場主導地位，市場佔有率將達到 93.94%。
  • 由於胸部X光檢查的有效性較低，因此其使用頻率降低。

最終用戶

市場涵蓋醫院、診所和診斷中心。

  • 醫院和診所憑藉其完善的基礎設施和強大的患者支持，預計到2026年將佔據 70.79%的市場佔有率，引領市場。
  • 由於合作夥伴關係的增加和服務範圍的擴大，預計該診斷中心將穩步發展。

區域趨勢

北美洲

北美地區到2025年達到 21.1億美元，預計到2026年將達到 23.1億美元。全面的篩檢計劃和較高的疾病盛行率支撐了該地區的領先地位。

歐洲

到2025年，歐洲的菸草市場規模達到11.5億美元，預計到2026年將成長至12.4億美元。該成長是由吸煙率上升和完善的醫療保健體系所推動的。

亞太地區

亞太地區菸草市場規模在2025年達3.8億美元，預計在2026年將達4.1億美元。菸草消費量的成長和政府的各項措施推動這項成長。

其他

  • 拉丁美洲：1.6億美元（2025年）→ 1.7億美元（2026年）
  • 中東和非洲：3000萬美元（2025年）→ 3000萬美元（2026年）

由於醫療基礎設施的改善，預計這些地區將經歷適度成長。

主要企業

市場上的主要企業包括Koninklijke Philips N.V.、Siemens Healthineers AG、Canon Medical Systems Corporation、GE Healthcare、FUJIFILM Holdings Corporation。這些公司正致力於創新、推出新產品和建立策略聯盟，以鞏固其市場地位。

主要行業趨勢

  • 2024年，推出新的篩檢項目和臨床測試，以提高早期檢測率。
  • 人工智慧輔助診斷工具和成像技術已獲得監管部門核准。
  • 各公司越來越關注非侵入性篩檢解決方案，例如液態生物檢體。

2026-2034年的年複合成長率為 9.61%。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 2025年主要地區肺癌發生率
  • 重大工業發展、併購和新產品發布。
  • 美國、歐洲和亞洲肺癌篩檢發展的法規環境
  • 肺癌篩檢的技術進步
  • 新冠疫情對肺癌篩檢的影響

第5章 2021-2034年全球肺癌篩檢市場分析、洞察與預測

  • 市場分析、洞察與預測：依癌症類型分類
    • 非小細胞肺癌（NSCLC）
    • 小細胞肺癌
  • 市場分析、洞察與預測：依診斷類型分類
    • 低劑量螺旋電腦斷層掃描
    • 胸部X光片
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院和診所
    • 診斷中心
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美肺癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲肺癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區肺癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太地區

第9章 拉丁美洲肺癌篩檢市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第10章 中東和非洲肺癌篩檢市場分析、洞察和預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Koninklijke Philips NV
    • Siemens Healthineers AG
    • GE Healthcare（General Electric Company）
    • Nuance Communications, Inc.
    • Eon
    • PenRad Technologies, Inc.
    • Volpara Solutions Limited.
    • Canon Medical Systems Corporation
    • FUJIFILM Holdings Corporation
    • Medtronic
Product Code: FBI101174

Growth Factors of lung cancer screening Market

The global lung cancer screening market was valued at USD 3.84 billion in 2025 and is projected to grow to USD 4.16 billion in 2026, reaching USD 8.67 billion by 2034, registering a CAGR of 9.61% during 2026-2034. North America dominated the market with a 55.13% share in 2025, driven by strong screening programs and advanced healthcare infrastructure.

Lung cancer remains one of the most prevalent and fatal cancers worldwide, primarily linked to tobacco consumption. Early detection through screening plays a critical role in reducing mortality, which is significantly boosting the adoption of advanced diagnostic technologies globally.

Market Trends

Technological Advancements in Screening

The market is witnessing rapid technological progress, particularly in screening methods such as low-dose computed tomography (LDCT), liquid biopsy, and AI-based diagnostic tools. These innovations are improving early detection rates while reducing the need for invasive procedures.

Emerging technologies such as nanoparticle-based sensors and AI-assisted imaging are transforming screening accuracy and efficiency. Additionally, the development of liquid biopsy tests is enabling non-invasive cancer detection, making screening more accessible and patient-friendly.

Market Growth Factors

Rising Prevalence of Lung Cancer

The increasing global incidence of lung cancer, largely due to smoking and lifestyle changes, is a major driver of market growth. Growing awareness regarding early diagnosis and the rising number of screening initiatives by healthcare organizations are further supporting market expansion.

Government programs and awareness campaigns are encouraging high-risk populations to undergo regular screening, thereby increasing the number of diagnostic procedures conducted annually.

Growing Adoption of Advanced Diagnostic Tools

The increasing use of advanced imaging technologies, coupled with favorable reimbursement policies in developed countries, is driving the adoption of screening solutions. Collaborations between biotechnology and healthcare companies are also fostering innovation in diagnostic techniques.

Restraining Factors

High Cost of Screening Tests

Despite technological advancements, the high cost associated with screening procedures, especially CT scans, limits their accessibility in low- and middle-income countries. Limited insurance coverage and inadequate healthcare infrastructure further restrict widespread adoption.

Additionally, the shortage of skilled radiologists and diagnostic professionals in developing regions poses a challenge to market growth.

Market Segmentation Analysis

By Cancer Type

The market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

  • The NSCLC segment dominates and is projected to hold 87.8% market share in 2026, owing to its higher prevalence globally.
  • The SCLC segment also contributes significantly due to rising awareness and screening initiatives.

By Diagnosis Type

The market is divided into low-dose spiral CT scans and chest X-rays.

  • The low-dose CT scan segment dominates with 93.94% share in 2026, driven by higher accuracy and proven mortality reduction benefits.
  • Chest X-rays are witnessing declining adoption due to lower effectiveness.

By End-user

The market includes hospitals & clinics and diagnostic centers.

  • Hospitals & clinics lead the market, accounting for 70.79% share in 2026, due to better infrastructure and higher patient preference.
  • Diagnostic centers are expected to grow steadily with increasing collaborations and service expansion.

Regional Insights

North America

North America accounted for USD 2.11 billion in 2025 and is projected to reach USD 2.31 billion in 2026. Strong screening programs and high disease prevalence support regional dominance.

Europe

Europe held USD 1.15 billion in 2025 and is expected to grow to USD 1.24 billion in 2026. Growth is driven by rising smoking rates and well-established healthcare systems.

Asia Pacific

Asia Pacific generated USD 0.38 billion in 2025 and is projected to reach USD 0.41 billion in 2026. Increasing tobacco consumption and government initiatives are fueling growth.

Rest of the World

  • Latin America: USD 0.16 billion (2025) -> USD 0.17 billion (2026)
  • Middle East & Africa: USD 0.03 billion (2025) -> USD 0.03 billion (2026)

These regions show gradual growth due to improving healthcare infrastructure.

Key Companies

Leading players in the market include Koninklijke Philips N.V., Siemens Healthineers AG, Canon Medical Systems Corporation, GE Healthcare, and FUJIFILM Holdings Corporation. These companies focus on innovation, product launches, and strategic partnerships to strengthen their market position.

Key Industry Developments

  • In 2024, new screening programs and clinical trials were launched to improve early detection.
  • AI-based diagnostic tools and imaging technologies received regulatory approvals.
  • Companies are increasingly focusing on non-invasive screening solutions such as liquid biopsies.

Conclusion

The lung cancer screening market is poised for strong growth, increasing from USD 3.84 billion in 2025 to USD 8.67 billion by 2034. Rising cancer prevalence, technological advancements, and government support for early diagnosis are key growth drivers. Although high costs and limited accessibility may hinder adoption in some regions, ongoing innovations and expanding screening programs will significantly enhance early detection and improve patient outcomes globally.

Growth Rate CAGR of 9.61% from 2026-2034

Segmentation By Cancer Type

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer

By Diagnosis Type

  • Low Dose Spiral CT Scan
  • Chest X-ray

By End User

  • Hospitals & Clinics
  • Diagnostic Centers

By Geography

  • North America (By Cancer Type, By Diagnosis Type, By End User, and By Country)
    • U.S.
    • Canada
  • Europe (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence of Lung Cancer, By Key Region, 2025
  • 4.2. Key Industry Developments, Merger, Acquisitions, and Product Launches
  • 4.3. Regulatory Scenario Imposed on the Development of Lung Cancer Screening in U.S., Europe, and Asia
  • 4.4. Technological Advancements in Lung Cancer Screening
  • 4.5. Impact of COVID-19 on Lung Cancer Screening

5. Global Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 5.1.2. Small Cell Lung Cancer
  • 5.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 5.2.1. Low Dose Spiral CT scan
    • 5.2.2. Chest X-ray
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Diagnostic Centers
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 6.1.2. Small Cell Lung Cancer
  • 6.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 6.2.1. Low Dose Spiral CT scan
    • 6.2.2. Chest X-ray
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Diagnostic Centers
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 7.1.2. Small Cell Lung Cancer
  • 7.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 7.2.1. Low Dose Spiral CT scan
    • 7.2.2. Chest X-ray
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Diagnostic Centers
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 8.1.2. Small Cell Lung Cancer
  • 8.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 8.2.1. Low Dose Spiral CT scan
    • 8.2.2. Chest X-ray
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Diagnostic Centers
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 9.1.2. Small Cell Lung Cancer
  • 9.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 9.2.1. Low Dose Spiral CT scan
    • 9.2.2. Chest X-ray
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Diagnostic Centers
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 10.1.2. Small Cell Lung Cancer
  • 10.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 10.2.1. Low Dose Spiral CT scan
    • 10.2.2. Chest X-ray
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Diagnostic Centers
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Koninklijke Philips N.V.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Siemens Healthineers AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GE Healthcare (General Electric Company)
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Nuance Communications, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Eon
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. PenRad Technologies, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Volpara Solutions Limited.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Canon Medical Systems Corporation
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. FUJIFILM Holdings Corporation
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Medtronic
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 02: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 03: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 04: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 05: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 06: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 07: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 08: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 09: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 10: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 11: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 12: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 14: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 15: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 18: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 19: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 20: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 22: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 23: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 01: Global Lung Cancer Screening Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 02: Global Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 03: Global Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025 & 2034
  • Figure 04: Global Lung Cancer Screening Market Value Share (%), by End User, 2025 & 2034
  • Figure 05: Global Lung Cancer Screening Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 06: North America Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 07: North America Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 08: North America Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 09: North America Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 10: North America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 11: North America Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 12: North America Lung Cancer Screening Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 13: North America Lung Cancer Screening Market Value Share (%), By Country, 2025
  • Figure 14: Europe Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 15: Europe Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 16: Europe Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 17: Europe Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 18: Europe Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 19: Europe Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 20: Europe Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 23: Asia Pacific Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 24: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 25: Asia Pacific Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 26: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 31: Latin America Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 32: Latin America Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 33: Latin America Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 34: Latin America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 35: Latin America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 36: Latin America Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 37: Latin America Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Latin America Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 40: Middle East & Africa Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 41: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 42: Middle East & Africa Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 43: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 44: Middle East & Africa Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 45: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Middle East & Africa Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025